Key result
Elevated flow-mediated dilation post-treatment linked to ~4.8-fold higher all-cause mortality in AL amyloidosis.
Why the study?
Peripheral vascular involvement at diagnosis of AL amyloidosis predicts increased mortality, but the clinical utility and prognostic value of assessing peripheral vascular and hemodynamic markers after treatment remained unknown.
Does post-treatment longitudinal assessment of peripheral vascular and hemodynamic markers predict all-cause mortality in patients with AL amyloidosis?
Cohort (n=140)
No
Does post-treatment longitudinal assessment of peripheral vascular and hemodynamic markers predict all-cause mortality in patients with AL amyloidosis?
In AL amyloidosis survivors, peripheral vascular and hemodynamic markers measured at 6 and 12 months post-treatment retain independent prognostic value for all-cause mortality and may aid in post-treatment risk stratification.
Answers are grounded in this paper and cite their sources.
Elevated post-treatment FMD was associated with higher mortality in AL amyloidosis; leaves open its role in risk stratification pending validation.
Background/Introduction Peripheral vascular involvement at diagnosis of AL amyloidosis is prognostic of increased mortality. However, the clinical utility of post-treatment vascular assessment remains unknown. Purpose To evaluate longitudinal changes and prognostic value of peripheral vascular and hemodynamic markers following treatment in AL amyloidosis patients. Methods We prospectively assessed 140 AL amyloidosis patients at baseline, 3 months, and 6-12 months post-treatment in our high-volume center of excellence in amyloidosis. Flow-mediated dilation (FMD), pulse wave velocity (PWV), augmentation index (AI@75) and central/peripheral blood pressures were measured. Patients were stratified by hematologic response (complete/very good response vs. partial/no response). Multivariable Cox regression evaluated associations between markers of vascular involvement with all-cause mortality with a maximum follow-up of 72 months, adjusting for age, Mayo stage, cardiac involvement, nerve involvement and baseline hypotension. Results At 3 months post-treatment, patients with complete hematologic response showed early FMD decrease from 3.95 (1.82-6.28) to 3.3 (1.38 5.85)(p=0.048) while all patients presented modest blood pressure reductions (p<0.05) regardeless of hematologic response. After 6 months, in all survivors, vascular markers converged regardeless of hematologic response depth (p=0.648-0.673). By multivariable analysis, at 6 months post treatment lower central SBP (HR 0.89 CI: 0.84, 0.95, p<0.001), pulse pressure (HR 0.94 CI: 0.91,0.98, p<0.003), PWV (HR 0.66 CI: 0.48, 0.92, p=0.015) and AI@75 (HR 0.91 CI: 0.86, 0.96, p= <0.001) and higher FMD (HR 1.18 CI: 1.01, 1.40, p=0.048) predicted worse outcomes. Moreover, elevated FMD (>6) at 12 months independently predicted increased mortality risk (HR 4.78, 95% CI 1.11, 20.49; p=0.036). Conclusions In survivors with AL-amyloidosis, after 6 months of treatment, vascular and hemodynamic markers tetain prognostic value independent of established predictors for the disease. These results suggest that longitudinal vascular assessment in AL-amyloidosis may be useful in post-treatment risk stratification of the disease.
No takes yet. Share an insight, caveat, or question.
Petropoulos et al. (2026) conducted a cohort in AL amyloidosis (n=140). Post-treatment peripheral vascular and hemodynamic markers (e.g., elevated FMD >6 at 12 months) vs. Lower FMD / reference vascular marker levels was evaluated on All-cause mortality (HR 4.78, 95% CI 1.11-20.49, p=0.036). Elevated flow-mediated dilation (>6) at 12 months post-treatment independently predicted increased all-cause mortality in AL amyloidosis.
Synapse has enriched 10 related papers. Consider them for comparative context: